Exocrine Pancreatic Insufficiency Therapeutics Market Size Worth $2.55 billion by 2026; Increasing Prevalence of Associated Disorders to Boost Sales

The global exocrine pancreatic insufficiency (EPI) therapeutics market size is set to touch USD 2.55 billion by 2026 as a result of rising demand for online retail pharmacies worldwide. As per the new report by Fortune Business Insights, titled “Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share & Industry Analysis, By Therapy (Pancreatic Enzyme Replacement Therapy (PERT), Nutritional Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026”, the market value stood at USD 1.49 billion in 2018 and is expected to showcase a CAGR of 6.5% from 2019 to 2026.

Spreading Awareness about EPI Therapeutics to Fuel Growth

Exocrine pancreatic insufficiency (EPI) is a relatively lesser known affliction. It basically describes a condition wherein the pancreas is unable to produce the necessary quantity of enzymes to digest food. While awareness about this condition was low, today it is steadily spreading, especially with regard to the adverse health effects the disorder has on patients. For instance, in the US, acute pancreatitis is one of the leading gastrointestinal causes raising the demand for exocrine pancreatic insufficiency drugs in the country. This is expected to be one of the prominent factors shaping the exocrine pancreatic insufficiency therapeutic market trends. 

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/exocrine-pancreatic-insufficiency-market-100652

Market Segmentation:

• By Therapy: In terms of therapy, the market is segmented into pancreatic enzyme replacement therapy (PERT) and nutritional therapy. Here, the pancreatic enzyme replacement therapy (PERT) segment is slated to lead this market owing to its conventional status and high efficiency and potency. Nutritional therapy segment will progress at a slower pace, but will gather momentum in the long-run.


• By Distribution Channel: Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies & drug stores, and others. Here, the hospital pharmacies segment will dominate on account of presence of and prescription of drugs by medical professionals in these facilities. The retail pharmacies & drug stores segment will hold the second largest share owing their efficient patient care delivery services.


• By Region: Geographically, the market is categorized into North America, Europe, Asia-Pacific, and Rest of the World. Here, North America is anticipated to have a commanding hold on the exocrine pancreatic insufficiency therapeutic market share in the forecast period as the region generated a revenue of USD 1.18 billion in 2018. The main factors driving the market in this region include increased R&D activities, rising adoption of advanced therapeutics, and growing prevalence and awareness of EPI and its associated disorders. The other regions are also expected to display steady growth throughout the forecast period.

Presence of a Few Key Players to Stiffen Competition

Competition in this market is likely to get bolstered as a result of the presence of a few large companies that are looking to entrench their position. The exocrine pancreatic insufficiency therapeutic market analysis shows that these players are strengthening their product portfolio and expanding their presence and operations beyond the boundaries of their home countries. Moreover, many companies are investing in conducting advanced trials to get regulatory approvals for their products.

Key Market Players:

• Janssen Pharmaceuticals, Inc.


• CHIESI Farmaceutici S.p.A.


•  AbbVie Inc.


•  AzurRx


•  Allergan

Key Industry Developments:

• October 2019: AzurRx BioPharma, Inc., company specializing in gastrointestinal therapies, announced that it has dosed the first patients having cystic fibrosis and suffering from severe EPI with MS1819-SD in combination with the standardized porcine enzyme replacement therapy (PERT). The aim of the study is to test the efficacy of the drug combo to treat the symptoms of EPI.


• March 2018: Anthera Pharmaceuticals, a biopharmaceutical engaged in treating disorders associated with cystic fibrosis, reported that its promising product for non-porcine pancreatic enzyme replacement therapy, Sollpura, did not deliver the expected results in the company’s clinical study, which was in its third phase.

The global exocrine pancreatic insufficiency therapeutic market is segmented as follows: